Targeted drug therapy: the platelet side.
Platelets
; 22(7): 479-84, 2011.
Article
em En
| MEDLINE
| ID: mdl-21973091
ABSTRACT
Targeted therapy is certainly considered the future of cancer treatment. Several new molecules targeting critical intracellular signaling actors, particularly kinases, are arriving in clinics and many other are under development. However, proteins targeted by these drugs are common to many cell types and are particularly implicated in the highly dynamic processes of platelet activation. Therefore, the effects of targeted drugs, including kinase inhibitors, on platelet activation have to be considered in clinical practice. Moreover, their analysis also represents an opportunity to increase our knowledge in platelet biology and physiology and to develop novel antiplatelet strategies. In this review we briefly describe the major platelet signaling pathways that may be affected by these new drugs and discuss some clinical implications of their use.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Plaquetas
/
Ativação Plaquetária
/
Inibidores de Proteínas Quinases
/
Terapia de Alvo Molecular
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Platelets
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
França